(919) 237-4897 info@t3dtherapeutics.com

T3D Therapeutics announced the creation of its Advisory Board with the addition of three members who are experts in the field of Alzheimer’s disease and other central nervous system disorders; Lawrence Friedhoff, M.D., Ph.D., FACP, Warren Strittmatter, M.D. and Joseph DeVeaugh-Geiss, M.D.

Dr. Lawrence Friedhoff was responsible for the development and launch of Aricept® the market leading Alzheimer’s disease drug. Dr. Friedhoff is the President and Founder of the Pharmaceutical Special Projects Group (PSPG), a pharmaceutical and biotechnology consulting firm. Prior to founding PSPG Dr. Friedhoff held positions as the Executive Vice President, R&D at Andrx Pharmaceuticals prior to its acquisition by Watson Laboratories. Prior to Andrx, Dr. Friedhoff had been the Executive Vice President of R&D at Eisai USA and Clinical Pharmacology Director at Bristol-Myers Squibb. Dr. Friedhoff has overseen the development and approval of six New Drug Applications including two blockbusters, Aricept(R) and Aciphex(R).

Dr. Strittmatter is Professor and former Chief of Neurology at Duke University Medical Center. He received his M.D. and Neurology Residency training at Duke University Medical Center, and then subsequently did post-doctoral research at the National Institutes of Health. Dr. Strittmatter is internationally recognized for his basic research in Alzheimer’s and Huntington’s disease. He was elected to the Association of American Physicians, the American Society for Clinical Investigation, and received the Alzheimer’s Association Zenith Award. He was recognized by the Institute for Scientific Information as the “Top 20 Scientists” in Neuroscience and Behavior for the decade 1992-2002. Dr. Strittmatter has published over 100 papers in peer-reviewed academic journals and has been awarded 12 U.S. Patents. Dr Strittmatter received his MD from Duke University.

Dr. DeVeaugh-Geiss is Consulting Professor of Psychiatry at Duke University Medical Center, Adjunct Professor of Psychiatry at the University of North Carolina at Chapel Hill, Visiting Professor of Pharmacology at the American University of the Caribbean, and Research Associate Professor of Psychiatry, SUNY Health Science Center, Syracuse, New York. From 2001 to 2006, he served as Director, CNS Division, Duke Clinical Research Institute, Durham NC. Prior to joining Duke Clinical Read MoreResearch Institute, Dr. DeVeaugh-Geiss spent 16 years leading CNS drug development programs in the pharmaceutical industry, initially at Ciba-Geigy and most recently as Vice President and International Director of CNS Clinical Research at GlaxoSmithKline. He has contributed to and managed the successful submission of 12 New Drug Applications (NDAs) and Supplemental New Drug Applications (sNDAs). Dr. DeVeaugh-Geiss is also Manager/Owner of the consulting company, BRAINSTORM CNS, LLC.